AMGN
$361.21-5.04 (-1.38%)
Amgen Inc.
Recent News
Grail CEO Bob Ragusa to retire
Josh Ofman, company president, will step into the top job. Guggenheim Securities analysts said the leadership change “has been in development for some time and is unrelated to the NHS trial readout."
This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) costs $6 a year on a $10,000 investment, holds 100 dividend stocks, and currently yields 3.39%. With the Fed funds rate sitting at 3.75% and most high-yield savings accounts paying in that same neighborhood, the yield gap is narrow. But SCHD adds something a savings account never will: price ... This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies
We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In. Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontinuing all ongoing clinical trials involving rocatinlimab, an experimental anti-OX40 monoclonal antibody that was previously […]
Amgen’s TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN)
In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs such as Amjevita, Aimovig, and Repatha, while also preparing for its March 11 presentation at the Leerink Global Healthcare Conference in Miami. Together with its recently reported double-digit revenue and EPS growth in 2025 and progress in obesity and oncology programs, these moves highlight Amgen’s focus on expanding access to its...